Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the ...

Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with ...

In patients with advanced ESCC treated with first-line tislelizumab plus chemotherapy, deeper responses and longer time to ...

Phase 2 trial of defactinib in combination with avutometinib in patients with advanced diffuse-type gastric cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...

Barrett's esophagus (BE) is a condition that arises when the lining of the esophagus is damaged by chronic gastroesophageal reflux disease (GERD). This condition is significant because it is the ...

Oral squamous cell carcinoma (OSCC) is an aggressive cancer, with prognosis influenced by clinical variables as well grading systems and perineural invasion (PNI), which are associated to poorer ...

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...